Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation

Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahadudheen, K., Islam, Md. Rafiqul, Iddawela, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775779/
https://www.ncbi.nlm.nih.gov/pubmed/26989536
http://dx.doi.org/10.1155/2016/2672671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775779/
https://www.ncbi.nlm.nih.gov/pubmed/26989536
http://dx.doi.org/10.1155/2016/2672671

Ejemplares similares